Filip Surmont

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

Carolyn S.P. Lam, Shun Kohsaka, Avraham Karasik et al. · Journal of the American College of Cardiology · 2018 · 466 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)

Mikhail Kosiborod, Marília Brito Gomes, Antonio Nicolucci et al. · Cardiovascular Diabetology · 2018 · 263 citations · Full text

Medicine, Internal Medicine, Clinical Epidemiology +12

SGLT-2 Inhibitors and Cardiovascular Risk

Matthew A. Cavender, Anna Norhammar, Kåre I. Birkeland et al. · Journal of the American College of Cardiology · 2018 · 129 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study

Marília Brito Gomes, Wolfgang Rathmann, B Charbonnel et al. · Diabetes Research and Clinical Practice · 2019 · 100 citations · Full text

Medicine, Endocrinology, Internal Medicine +16

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

Shun Kohsaka, Carolyn S.P. Lam, Dae Jung Kim et al. · The Lancet Diabetes & Endocrinology · 2020 · 93 citations · Full text

Medicine, Cardiology, Pharmacology +12